Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.
Charu AggarwalJeffrey C ThompsonAustin L ChienKatie J QuinnWei-Ting HwangTaylor A BlackStephanie S YeeTheresa E ChristensenMichael J LaRiviereBenjamin A SilvaKimberly C BanksRebecca J NagyElena HelmanAbigail T BermanChristine A CiunciAditi P SinghJeffrey S WasserJoshua M BaumlCorey J LangerRoger B CohenErica L CarpenterPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
pTMB ≥ 16 mut/Mb is associated with improved PFS after first-line standard-of-care pembrolizumab-based therapy in mNSCLC. STK11/KEAP1/PTEN and ERBB2 mutations may help identify pTMB-high patients unlikely to respond. These results should be validated in larger prospective studies.